Cotrimoxazole
- PDF / 169,399 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 111 Downloads / 167 Views
1 S
Thrombocytopenia, hepatitis and renal failure: 3 case reports In an observational retrospective study conducted from January 1994 through December 2006 involving 83 patients, 3 men aged 29–45 years* were described, who developed thrombocytopenia, hepatitis or renal failure during treatment with cotrimoxazole for toxoplasmic encephalitis (TE) [routes, durations of treatments to reactions onsets and outcomes not stated]. The men, who had AIDS, presented with a first episode of TE. The men started receiving treatment with cotrimoxazole [trimethoprim/sulfamethoxazole] at a fixed ratio of 1:5. After 4–6 weeks, the curative treatment of TE was stopped, and the men received secondary prophylaxis with cotrimoxazole 160/800mg once a day. Subsequently, the men developed thrombocytopenia (1 patient), hepatitis (1 patient) and renal failure (1 patient) secondary to the cotrimoxazole therapy. * Identifying patient details have been obtained through direct communication with the author. Beraud G, et al. Cotrimoxazole for treatment of cerebral toxoplasmosis: an observational cohort study during 1994-2006. American Journal of Tropical Medicine and Hygiene 803497862 80: 583-587, No. 4, 1 Apr 2009. Available from: URL: http://doi.org/10.4269/ajtmh.2009.80.583
0114-9954/20/1818-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 22 Aug 2020 No. 1818
Data Loading...
